BioCentury | Oct 3, 2016
Finance

All in the family

...wants more firepower and is bringing additional offices into the fold. The resulting firm, dubbed Cerus...
...$500 million. The overarching goal remains creating life science newcos on the West Coast, but Cerus...
...exceed expectations, we'll hire a full management team and allow the company to become public." Cerus...
BioCentury | Aug 11, 2016
Company News

Management tracks

...associate clinical professor of ophthalmology at the University of California San Francisco . Hematology company Cerus Corp....
BioCentury | Aug 1, 2016
Company News

Cerus, U.S. Department of Health and Human Services infectious news

...HHS’s Biomedical Advanced Research and Development Authority (BARDA) granted Cerus a five-year contract worth up to...
...up to $180.5 million to develop its Intercept Blood System for red blood cells . Cerus...
...broader implementation in areas of Zika virus risk, clinical and regulatory development, manufacturing and scale-up. Cerus...
BioCentury | Dec 21, 2015
Analyst Picks & Changes

Analyst picks & changes

...& changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 12/18 cls Cerus Corp....
...25% in the past six months. His target is $6.50. In late 2014, FDA approved Cerus'...
...products. Khurshid maintained a conservative 2016 revenue estimate of $44M vs. $47M for consensus, noting Cerus'...
BioCentury | Aug 17, 2015
Company News

Cerus, SunCoast Blood Bank Inc. sales and marketing update

...SunCoast implemented Cerus’ Intercept Blood System for platelets at bloodbanks in southwest Florida. Cerus said it...
...pathogen inactivation system uses light-activated molecules to crosslink DNA and RNA to prevent pathogen replication. Cerus...
...Fresenius SE & Co. KGaA (Xetra:FRE; OTCQX:FSNUY, Bad Homburg, Germany) (see BioCentury, Dec. 22, 2014). Cerus Corp....
BioCentury | Jun 9, 2015
Company News

Management tracks

...Hematology play Cerus Corp. (NASDAQ:CERS) named Richard Benjamin CMO, effective July 13. Benjamin was CMO for the...
BioCentury | Apr 6, 2015
Finance

Fundamental rally

...Inc. (NASDAQ:STML) 1/8/15 $68.6 $277.8 $257.9 -7% Cempra Inc. (NASDAQ:CEMP) 1/7/15 $147.9 $1,047.9 $1,493.6 43% Cerus Corp....
BioCentury | Feb 9, 2015
Clinical News

Intercept Blood System for red blood cells: Phase III data

...cardiovascular surgery patients with acute anemia showed that transfusion of red blood cells treated with Cerus’...
...7-day treatment period that included the day of surgery and 6 days post-operatively. In 2H16, Cerus...
...the Intercept Blood System for red blood cells for CE Mark approval in the EU. Cerus Corp....
BioCentury | Feb 9, 2015
Clinical News

Intercept Blood System for red blood cells: Preliminary Phase II data

...II trial in 26 healthy volunteers showed that transfusion of red blood cells treated with Cerus’...
...blood cells, 1 with Intercept-treated cells and the other with untreated control cells. In 2H16, Cerus...
...the Intercept Blood System for red blood cells for CE Mark approval in the EU. Cerus Corp....
BioCentury | Jan 12, 2015
Financial News

Cerus completes follow-on

Cerus Corp. (NASDAQ:CERS), Concord, Calif. Business: Cancer, Infectious, Hematology Date completed: 2015-01-07 Type: Follow-on Raised: $70 million Shares: 12.7 million Price: $5.50 Shares after offering: 89.9 million Underwriters: Cowen; Robert W. Baird; Wedbush; Stephens; BTIG;...
Items per page:
1 - 10 of 284
BioCentury | Oct 3, 2016
Finance

All in the family

...wants more firepower and is bringing additional offices into the fold. The resulting firm, dubbed Cerus...
...$500 million. The overarching goal remains creating life science newcos on the West Coast, but Cerus...
...exceed expectations, we'll hire a full management team and allow the company to become public." Cerus...
BioCentury | Aug 11, 2016
Company News

Management tracks

...associate clinical professor of ophthalmology at the University of California San Francisco . Hematology company Cerus Corp....
BioCentury | Aug 1, 2016
Company News

Cerus, U.S. Department of Health and Human Services infectious news

...HHS’s Biomedical Advanced Research and Development Authority (BARDA) granted Cerus a five-year contract worth up to...
...up to $180.5 million to develop its Intercept Blood System for red blood cells . Cerus...
...broader implementation in areas of Zika virus risk, clinical and regulatory development, manufacturing and scale-up. Cerus...
BioCentury | Dec 21, 2015
Analyst Picks & Changes

Analyst picks & changes

...& changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 12/18 cls Cerus Corp....
...25% in the past six months. His target is $6.50. In late 2014, FDA approved Cerus'...
...products. Khurshid maintained a conservative 2016 revenue estimate of $44M vs. $47M for consensus, noting Cerus'...
BioCentury | Aug 17, 2015
Company News

Cerus, SunCoast Blood Bank Inc. sales and marketing update

...SunCoast implemented Cerus’ Intercept Blood System for platelets at bloodbanks in southwest Florida. Cerus said it...
...pathogen inactivation system uses light-activated molecules to crosslink DNA and RNA to prevent pathogen replication. Cerus...
...Fresenius SE & Co. KGaA (Xetra:FRE; OTCQX:FSNUY, Bad Homburg, Germany) (see BioCentury, Dec. 22, 2014). Cerus Corp....
BioCentury | Jun 9, 2015
Company News

Management tracks

...Hematology play Cerus Corp. (NASDAQ:CERS) named Richard Benjamin CMO, effective July 13. Benjamin was CMO for the...
BioCentury | Apr 6, 2015
Finance

Fundamental rally

...Inc. (NASDAQ:STML) 1/8/15 $68.6 $277.8 $257.9 -7% Cempra Inc. (NASDAQ:CEMP) 1/7/15 $147.9 $1,047.9 $1,493.6 43% Cerus Corp....
BioCentury | Feb 9, 2015
Clinical News

Intercept Blood System for red blood cells: Phase III data

...cardiovascular surgery patients with acute anemia showed that transfusion of red blood cells treated with Cerus’...
...7-day treatment period that included the day of surgery and 6 days post-operatively. In 2H16, Cerus...
...the Intercept Blood System for red blood cells for CE Mark approval in the EU. Cerus Corp....
BioCentury | Feb 9, 2015
Clinical News

Intercept Blood System for red blood cells: Preliminary Phase II data

...II trial in 26 healthy volunteers showed that transfusion of red blood cells treated with Cerus’...
...blood cells, 1 with Intercept-treated cells and the other with untreated control cells. In 2H16, Cerus...
...the Intercept Blood System for red blood cells for CE Mark approval in the EU. Cerus Corp....
BioCentury | Jan 12, 2015
Financial News

Cerus completes follow-on

Cerus Corp. (NASDAQ:CERS), Concord, Calif. Business: Cancer, Infectious, Hematology Date completed: 2015-01-07 Type: Follow-on Raised: $70 million Shares: 12.7 million Price: $5.50 Shares after offering: 89.9 million Underwriters: Cowen; Robert W. Baird; Wedbush; Stephens; BTIG;...
Items per page:
1 - 10 of 284